These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 21381892)

  • 1. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
    Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes.
    Giraldo P; Nomdedeu B; Loscertales J; Requena C; de Paz R; Tormo M; Navarro P; Benedit P; Gasquet JA;
    Cancer; 2006 Dec; 107(12):2807-16. PubMed ID: 17115424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial.
    Charu V; Belani CP; Gill AN; Bhatt M; Tomita D; Rossi G; Ben-Jacob A
    Oncologist; 2007 Jun; 12(6):727-37. PubMed ID: 17602062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes.
    Gabrilove J; Paquette R; Lyons RM; Mushtaq C; Sekeres MA; Tomita D; Dreiling L
    Br J Haematol; 2008 Jul; 142(3):379-93. PubMed ID: 18540943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R; Lillie T; Tomita D; Balducci L
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
    Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
    Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
    Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
    J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT).
    Martelli O; Garassino M; Sacchetta S; Caristo R; Zivi A; Cerbone L; Mancuso A
    Anticancer Res; 2008; 28(3B):1767-71. PubMed ID: 18630457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
    Mahajan S; Boulton H; Gokal R
    J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes.
    Musto P; Lanza F; Balleari E; Grossi A; Falcone A; Sanpaolo G; Bodenizza C; Scalzulli PR; La Sala A; Campioni D; Ghio R; Cascavilla N; Carella AM
    Br J Haematol; 2005 Jan; 128(2):204-9. PubMed ID: 15638854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy.
    Ichinose Y; Seto T; Nishiwaki Y; Ohe Y; Yamada Y; Takeda K; Saijo N; Hotta T
    Jpn J Clin Oncol; 2010 Jun; 40(6):521-9. PubMed ID: 20508073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome.
    Spiriti MA; Latagliata R; Niscola P; Cortelezzi A; Francesconi M; Ferrari D; Volpe E; Clavio M; Grossi A; Reyes MT; Musto P; Mitra ME; Azzarà A; Pagnini D; D'Arena G; Spadano A; Balleari E; Pecorari P; Capochiani E; De Biasi E; Perego D; Monarca B; Pisani F; Scaramella G; Petti MC
    Ann Hematol; 2005 Mar; 84(3):167-76. PubMed ID: 15592833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.
    Stasi R; Abruzzese E; Lanzetta G; Terzoli E; Amadori S
    Ann Oncol; 2005 Dec; 16(12):1921-7. PubMed ID: 16166176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
    Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.